The deal, the second between South San Francisco-based Genentech and AC Immune, potentially could be worth about $418 million, the companies said Monday.
The worldwide license agreement and research collaboration centers on AC Immune’s anti-Tau antibodies as treatments for Alzheimer’s and other neurodegenerative diseases.
No comments:
Post a Comment